Critical Contrast: Liminatus Pharma (LIMN) versus Its Competitors

Liminatus Pharma (NASDAQ:LIMN) is one of 861 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Liminatus Pharma to similar businesses based on the strength of its analyst recommendations, valuation, dividends, profitability, institutional ownership, earnings and risk.

Insider and Institutional Ownership

47.9% of shares of all “Biotechnology” companies are held by institutional investors. 19.4% of Liminatus Pharma shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Liminatus Pharma has a beta of 5.35, indicating that its share price is 435% more volatile than the S&P 500. Comparatively, Liminatus Pharma’s competitors have a beta of 1.23, indicating that their average share price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Liminatus Pharma and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1	0	0	0	1.00
Liminatus Pharma Competitors	9347	14858	44433	1502	2.54

As a group, “Biotechnology” companies have a potential upside of 58.01%. Given Liminatus Pharma’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Liminatus Pharma has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Liminatus Pharma and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Liminatus Pharma	N/A	-$10.21 million	-9.00
Liminatus Pharma Competitors	$682.71 million	$8.79 million	-11.98

Liminatus Pharma’s competitors have higher revenue and earnings than Liminatus Pharma. Liminatus Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Liminatus Pharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Liminatus Pharma Competitors	-9,375.28%	-127.83%	-33.50%

Summary

Liminatus Pharma competitors beat Liminatus Pharma on 8 of the 13 factors compared.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.